What’s the Buzz? Cannabis-derived products are at a dynamic legal and regulatory crossroads at both the state and federal level. While cannabis-derived substances above 0.3% THC are still illegal at the federal level, states are continuing to legalize cannabis for medical and/or recreational use; many states even designated cannabis businesses as “essential” during the initial phases of the COVID-19 pandemic. Simultaneously, CBD products, many with unsubstantiated drug claims or containing toxic substances, continue to proliferate despite scant FDA oversight. This conference will examine the present reality of this unique industry from both a legal and practical perspective and guide attendees on how to navigate this constantly changing legal environment. Industry experts will untangle the issues related to CBD, cannabis, and other cannabinoids, various regulated product areas (e.g., topicals, supplements, edibles, drugs), and state vs. federal regulation.